BioVaxys Technology (BVAXF) Financial Statements
BioVaxys Technology Financial Overview
BioVaxys Technology's market cap is currently $1.46M. The company's EPS TTM is $-0.24; its P/E ratio is -0.91; BioVaxys Technology is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Oct 24 | Apr 24 | Jan 23 | Jan 22 | Jan 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -3.30M | $ -2.40M | $ -4.08M | $ -6.44M | $ -1.10M |
| EBITDA | $ -3.95M | $ -5.28M | $ 0.00 | $ -478.68K | $ -93.56K |
| Net Income | $ -3.95M | $ -7.69M | $ -11.73M | $ -6.46M | $ -1.17M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 211.81K | $ 977.00 | $ 141.90K | $ 593.12K | $ 2.42M |
| Total Assets | $ 1.30M | $ 113.48K | $ 865.56K | $ 8.50M | $ 10.46M |
| Total Debt | $ 68.08K | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -143.73K | $ -977.00 | $ -141.90K | $ -593.12K | $ -2.42M |
| Total Liabilities | $ 3.22M | $ 3.49M | $ 1.64M | $ 326.86K | $ 900.09K |
| Stockholders' Equity | $ -1.92M | $ -3.37M | $ -773.53K | $ 8.18M | $ 9.56M |
| Cash Flow | |||||
| Free Cash Flow | $ -2.92M | $ -1.05M | $ -1.57M | $ -5.29M | $ -1.23M |
| Operating Cash Flow | $ -1.86M | $ -1.05M | $ -1.57M | $ -5.29M | $ -1.23M |
| Investing Cash Flow | $ -1.06M | $ 0.00 | $ 0.00 | $ 0.00 | $ 61.36K |
| Financing Cash Flow | $ 3.13M | $ 917.10K | $ 1.11M | $ 3.44M | $ 3.35M |
Currency in CAD